Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Affimed (GB:0HL9)
LSE:0HL9
Holding GB:0HL9?
Track your performance easily
0HL9 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.83 - $8.90
Previous Close$3.14
Volume452.00
Average Volume (3M)1.58K
Market Cap
$47.81M
Enterprise Value-$10.06M
Total Cash (Recent Filing)€72.05M
Total Debt (Recent Filing)€19.35M
Price to Earnings (P/E)―
Beta2.35
Next Earnings
Nov 12, 2024EPS Estimate
-$1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding15,227,463
10 Day Avg. Volume1,249
30 Day Avg. Volume1,579
Standard Deviation0.24
R-Squared0.20
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.83
Price to Sales (P/S)5.19
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.50Price Target Upside138.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Affimed News
PremiumCompany Announcements
Affimed N.V. Announces Upcoming EGM
PremiumCompany Announcements
Affimed N.V. Faces Substantial Mid-Year Losses
PremiumCompany Announcements
Affimed Appoints New CEO to Bolster Growth
PremiumCompany Announcements
Affimed Shareholders Approve Key ResolutionsBulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPositive early-stage study results indicate robust efficacy and a favorable safety profile for AFM24 with atezolizumab.
Financial Performance4Q23 net loss per share was better than consensus estimates, indicating a more favorable financial performance than expected.
ValuationAffimed's valuation is considered to be undervalued compared to peers, suggesting potential for growth.
Bears Say
Financial PerformanceThe company reported total revenues of €0.2M and a net loss of €1.27 per share.
RisksRisks to the company include clinical, regulatory, commercial, financial, and intellectual property challenges.
ValuationAnalyst adjusts price target from $30 to $25 based on updates to the Discounted Cash Flow model, reflecting a more conservative valuation.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.60% Mutual Funds
0.04% Other Institutional Investors
98.28% Public Companies and
Individual Investors
0HL9 FAQ
What was Affimed’s price range in the past 12 months?
Affimed lowest share price was $2.83 and its highest was $8.89 in the past 12 months.
What is Affimed’s market cap?
Currently, no data Available
When is Affimed’s upcoming earnings report date?
Affimed’s upcoming earnings report date is Nov 12, 2024 which is in 32 days.
How were Affimed’s earnings last quarter?
Affimed released its earnings results on Sep 05, 2024. The company reported -$1.109 earnings per share for the quarter, missing the consensus estimate of -$1.064 by -$0.045.
Is Affimed overvalued?
According to Wall Street analysts Affimed’s price is currently Undervalued.
Does Affimed pay dividends?
Affimed does not currently pay dividends.
What is Affimed’s EPS estimate?
Affimed’s EPS estimate is -$1.01.
How many shares outstanding does Affimed have?
Affimed has 15,227,463 shares outstanding.
What happened to Affimed’s price movement after its last earnings report?
Affimed reported an EPS of -$1.109 in its last earnings report, missing expectations of -$1.064. Following the earnings report the stock price went down -1.065%.
Which hedge fund is a major shareholder of Affimed?
Among the largest hedge funds holding Affimed’s share is Baker Bros Advisors LP. It holds Affimed’s shares valued at N/A.
---
Affimed Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.50 (138.85% Upside)
$7.50 (138.85% Upside)
Blogger Sentiment
Bullish
GB:0HL9 Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.64%
12-Months-Change
Fundamentals
Return on Equity
-123.53%
Trailing 12-Months
Asset Growth
-61.22%
Trailing 12-Months
Company Description
Affimed
Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
---
0HL9 Company Deck
---
0HL9 Earnings Call
Q2 2024
0:00 / 0:00
---
0HL9 Stock 12 Month Forecast
Average Price Target
$7.50
▲(138.85% Upside)
Technical Analysis
Affimed
―
Adaptimmune Therapeutics
―
Immutep
―
Karyopharm Therapeutics
―
Kura Oncology
―
Best Analysts Covering 0HL9
1 Year
1 Year Success Rate
1/18 ratings generated profit
1 Year Average Return
-47.81%
reiterated a buy rating 4 months ago
Copying Daina Graybosch's trades and holding each position for 1 Year would result in 5.56% of your transactions generating a profit, with an average return of -47.81% per trade.
---